On March 30th , Grandpharma (00512.HK) received good news that it stood out from thousands of Hong Kong listed companies based on a comprehensive review of the company’s performance, operational capability, profitability and corporate governance in recent years and won the “Third New Fortune Best Ir Hong Kong (H shares) “. This is also a renewed recognition of its strength and value from the capital market after Grandpharma won the “The Fourth Annual Most Valuable Golden Hong Kong Stock Pharmaceutical and Medical Company” award earlier this year.
In the future, Grandpharma will make use of its comprehensive advantages and continue to develop its technical and brand medicine products, and continue to enrich the group’s innovative product pipeline by adhering to a dual-wheel-drive development strategy of independent R & D and conducting domestic and overseas investment and acquisition at the same time. Meanwhile, Grandpharma will consolidate and strengthen its existing areas of strength, and gradually establish the leading position in the market.
